Co-targeting oncogenic pathways in advanced prostate cancer

共同靶向晚期前列腺癌的致癌途径

基本信息

批准号：
9252438
负责人：
KAREN M CICHOWSKI
金额：
$ 38.12万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-04-01 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9252438
关键词：
Ablation American Androgen Receptor Androgens Automobile Driving Biochemical CDK2 gene Cancer Model Cancer Patient Castration Cell Cycle Cell Death Cell Proliferation Cessation of life ChIP-seq Chemicals Clinical Clinical Trials Combined Modality Therapy Complex Data Development Diagnosis Disease Drug Combinations Drug Targeting EZH2 gene Early Diagnosis Enhancers Epigenetic Process Gene Silencing Genes Genetic Genetic Transcription Genomic approach Genomics Goals Growth In Vitro Individual Lead Lymphoma Malignant Neoplasms Malignant neoplasm of prostate Mediating Modeling Molecular Mutate Neoplasm Metastasis Oncogenes Oncogenic PPAR gamma PTEN gene Pathway interactions Patients Play Polycomb Process Refractory Reporting Resistance Role Signal Transduction Therapeutic Therapeutic Effect Xenograft Model Xenograft procedure advanced disease castration resistant prostate cancer clinical translation curative treatments defined contribution effective therapy histone methyltransferase in vivo inhibitor/antagonist insight killings men mortality novel overexpression pre-clinical preclinical study prostate cancer cell public health relevance response screening targeted agent targeted treatment treatment response tumor tumor progression

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer is the most frequently diagnosed non-dermatological malignancy in North American men. While screening and early detection have reduced mortality, there is still no curative treatment for advanced disease. As such all patients that develop castration-resistant tumors will ultimately die from their disease. Therefore developing an effective therapy for advanced prostate cancer represents an important unmet clinical need. By targeting two important oncogenic pathways we have identified a combination therapy that kills castration-resistant prostate cancer. Notably, while many (failed) targeted therapies have been shown to slow prostate cancer growth, this drug combination actually causes frank tumor regression in vivo in several models. The goal of this project is to deconstruct the mechanism by which these agents function, use this insight to identify the optimal drugs/targets, and validate the therapeutic effects of these agents in patient-derived xenograft (PDX) models. This will be accomplished through cellular, epigenetic, and genomic approaches and by conducting additional preclinical studies in vivo. These studies will not only provide invaluable preclinical data to guide the development of a clinical trial, but will uncover mechanisms that kill castration- resistant prostate cancer, which may ultimately lead to the development of additional therapeutic strategies.

描述（由适用提供）：前列腺癌是北美男性最常被诊断出的非德学恶性肿瘤。尽管筛查和早期检测降低了死亡率，但仍未治疗晚期疾病的治疗方法。因此，所有发展持cast割肿瘤的患者最终都会死于疾病。因此，为晚期前列腺癌开发有效的疗法是重要的未满足临床需求。通过针对两种重要的致癌途径，我们已经确定了一种杀死耐cast割前列腺癌的联合疗法。值得注意的是，尽管已显示许多（失败的）靶向疗法会减缓前列腺癌的生长，但这种药物组合实际上会在几种模型中导致体内弗兰克肿瘤的消退。该项目的目的是解构这些药物发挥作用的机制，使用此见解来识别最佳药物/靶标，并验证这些药物在患者衍生的异种移植（PDX）模型中的治疗作用。这将通过细胞，表观遗传和基因组方法以及在体内进行其他临床前研究来实现。这些研究不仅将提供宝贵的临床前数据来指导临床试验的发展，而且还将发现杀死耐cast割前列腺癌的机制，这最终可能导致额外的治疗策略的发展。